Fused PI3Kδ Inhibitor Compounds for Selective Isoform Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents are inadequate in modulating the activity of phosphoinositide 3-kinases (PI3Ks), which are involved in inflammatory disorders, immune-based diseases, and cancer, necessitating the development of new or improved agents to effectively target these pathways.
Innovation Solution
Development of specific compounds, such as those represented by Formula I and Formula Ia, which modulate the activity of PI3K kinases, allowing for the treatment of diseases associated with abnormal PI3K expression or activity, including inflammatory disorders, immune-based diseases, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used to modulate PI3K activity, then some level of disease treatment is achieved, but the therapeutic efficacy is inadequate
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of PI3K modulating agents through various substitutions and modifications to the core chemical framework. This includes changing functional groups, molecular weight, and chemical composition to optimize both therapeutic efficacy and selectivity for different PI3K isoforms, thereby resolving the contradiction between adequate therapy and limited modulation capability
Solution Approach 2:
The invention utilizes composite materials by combining multiple chemical moieties and structural elements into a single pharmaceutical agent. The compounds integrate various functional groups and structural features that work synergistically to achieve enhanced PI3K modulation, improved bioavailability, and increased therapeutic effectiveness, thus addressing the insufficiency of current single-component agents
2Measurement precision
If selective PI3K inhibitors are developed to target specific isoforms, then disease treatment specificity is improved, but the complexity of drug development increases
Solution Approach 1:
The patent applies segmentation by designing compounds that can selectively target specific PI3K isoforms (α, β, γ, or δ) through tailored molecular structures. Each compound variant is optimized to interact with particular isoform characteristics, enabling precise modulation of individual PI3K family members while simplifying the development pathway for isoform-specific therapeutics
Solution Approach 2:
The invention employs universality by creating a core chemical framework that can be adapted to target multiple PI3K isoforms through systematic modifications. This multi-functional approach allows a single base structure to serve as a prototype for developing inhibitors against different PI3K family members, reducing overall development complexity while maintaining isoform selectivity
Data Source
AI summary
The present invention provides fused derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.